Names | |
---|---|
IUPAC name
N-{[(1R,2R,3S,4S)-2-Hydroxybornan-3-yl]carbamoyl}-4-methylbenzene-1-sulfonamide
| |
Systematic IUPAC name
N-{[(1S,2S,3R,4R)-3-Hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]carbamoyl}-4-methylbenzene-1-sulfonamide | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.043.735 |
EC Number |
|
KEGG |
|
MeSH | C073323 |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C18H26N2O4S | |
Molar mass | 366.48 g/mol |
Pharmacology | |
A10BB04 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Glibornuride (INN) is an anti-diabetic drug from the group of sulfonylureas.[1] It is manufactured by MEDA Pharma and sold in Switzerland under the brand name Glutril.[2]
Gliburnide is an endo-endo derivative made from camphor-3-carboxamide by borohydride reduction (exo approach), followed by Hofmann rearrangement to carbamate, followed by displacement with sodium tosylamide.
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||